Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03568448 · ClinicalTrials.gov registry record
Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging
A clinical trial of HER2-Negative Breast Cancer, sponsored by New Mexico Cancer Research Alliance.
- Active
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT03568448: Active study of HER2-Negative Breast Cancer, sponsored by New Mexico Cancer Research Alliance.
NCT03568448 is a study of HER2-Negative Breast Cancer that is active but no longer recruiting, run by New Mexico Cancer Research Alliance. The registered enrollment target is 30 participants, below the 254-participant average among 49 other HER2-Negative Breast Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03568448, a study of HER2-Negative Breast Cancer, is active but no longer recruiting, sponsored by New Mexico Cancer Research Alliance.
- ACTIVE NOT RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will assess whether changes in total choline concentration \[tCho\] during neoadjuvant chemotherapy (NAC) are predictive of pathologic complete response (pCR) in patients with HER2 negative breast cancer (HNBC) appropriate for NAC, and compare these findings with dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). The objective is to assess the predictive value of changes in the concentration and spatial extent of tCho within the tumor during NAC.
Primary Outcome
In this study changes in total choline concentration \[tCho\] during neoadjuvant chemotherapy (NAC) will be evaluated by performing a high-speed magnetic resonance spectroscopic imaging (MRSI) at baseline prior to first cycle NAC, after first cycle NAC, and prior to second cycle NAC.
Conditions Studied
Interventions
- OTHER Response monitoring (no intervention)
Study Locations (1)
New Mexico
- University of New Mexico Comprehensive Cancer Center - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-04-16 |
| Est. Completion | 2027-12-31 |
What the registry record for NCT03568448 still lists
NCT03568448 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 254-participant average among 49 other HER2-Negative Breast Cancer trials with a reported enrollment target (88% lower).
The record links to 1 condition, with HER2-Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Response monitoring (no intervention) is the first listed.
NCT03568448 reports a single indexed study location in New Mexico.
Frequently Asked Questions
What is clinical trial NCT03568448 about?
NCT03568448 is a clinical study titled "Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging". The study will assess whether changes in total choline concentration \[tCho\] during neoadjuvant chemotherapy (NAC) are predictive of pathologic complete response (pCR) in patients with HER2 negative breast cancer (HNBC) appropriate for NAC, and compare these findings with dynamic contrast enhanced ...
What is the current status of trial NCT03568448?
This trial is currently active not recruiting. The enrollment target is 30 participants. The study started on 2018-04-16. Estimated completion is 2027-12-31.
What conditions does trial NCT03568448 study?
This clinical trial studies the following conditions: HER2-Negative Breast Cancer.
What interventions are being tested in trial NCT03568448?
The interventions under investigation include: Response monitoring (no intervention) (OTHER).
Who is sponsoring clinical trial NCT03568448?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03568448 being conducted?
This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03568448's enrollment target sits among peer trials
30 34th of 49 higher than 14 of 49 other HER2-Negative Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HER2-Negative Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
RECRUITING · Phase 2
-
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RECRUITING · Phase 1
-
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI